Skip to content

Bipolar Ventricular Tachycardia (VT) Study

Bipolar Catheter Ablation for the Treatment of Refractory Scar-Related Ventricular Arrhythmia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02374476
Enrollment
145
Registered
2015-02-27
Start date
2015-02-18
Completion date
2020-09-30
Last updated
2022-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular Tachycardia

Keywords

VT, Refractory VT, VT Storm, Ventricular Fibrillation, V Fib, VF

Brief summary

This non-randomized study will examine the safety and efficacy of irrigated bipolar radiofrequency (RF) ablation in the treatment of ventricular tachycardia (VT) in patients for whom standard VT unipolar RF ablation has been unsuccessful. VT is a serious abnormality of the heart's electrical system. Ablation is a procedure that cauterizes heart tissue using catheters (long tubes that can be moved within or along the outside of the heart). Cauterizing the heart tissue is accomplished by using heat to damage the abnormal heart tissue that is not working well so that it can stop affecting the rest of the heart. Usually, heat is delivered using a unipolar catheter, in which energy travels from the catheter tip to a grounding pad. This research study seeks to find out if a bipolar ablation catheter, in which the energy travels between two catheter tips on either side of the heart muscle, can be used to eliminate the arrhythmia when the unipolar ablation is unsuccessful. The hypothesis is that the increased current density and improved rates of transmural lesion creation seen with bipolar RF ablation will lead to successful arrhythmia termination with minimal or no increased risk of complication.

Detailed description

STUDY OBJECTIVE This study will examine the role of irrigated bipolar radiofrequency (RF) ablation for the treatment of intramural ventricular tachycardia in patients who have failed standard unipolar RF ablation. The hypothesis is that the increased current density and improved rates of transmural lesion creation seen with bipolar RF ablation will lead to successful arrhythmia termination with minimal or no increased risk of complication. INTRODUCTION, RATIONALE Radiofrequency (RF) ablation is the most commonly employed method for the catheter treatment of cardiac arrhythmias. Myocardial scar serves as the most frequent substrate for the genesis of both atrial and ventricular arrhythmia. Such scar frequently contains surviving myocyte bundles interspersed with fibrotic tissue, which leads to slow conduction. Areas of denser fibrosis cause conduction block. When appropriately arranged, conduction through or around these scars leads to the creation of a reentry circuit through which an arrhythmia is generated and maintained. Each reentry circuit contains within it an area called the isthmus, a portion of the circuit located in a position intimately related to the scar border zone. Electrical activation travels slowly through the isthmus before breaking out into normal myocardium. Ablation at the site of an isthmus will terminate a reentrant tachycardia. A variety of techniques, including electroanatomic mapping and activation, entrainment, and substrate mapping, are employed during electrophysiologic (EP) study to identify areas of myocardial scar and potential isthmus sites. Points or lines of ablation using RF energy are then created in an attempt to interrupt the reentry circuit. Typically, unipolar RF energy is applied via a catheter tip electrode to the endocardial or epicardial surface of the heart and grounded via an electrode pad placed on the patient's skin. RF energy in this setting is dispersed through the entirety of the tissue between catheter tip and grounding pad. The standard 7-French, 4-mm tip catheters are highly successful at ablating circuits located within a few millimeters of the catheter tip. A focal, 1mm area of resistive heating occurs within the myocardium immediately in contact with the catheter tip; myocardial cell death occurs several millimeters more deeply through passive, conductive heating, which spreads outward from the contact point. While the standard catheter is effective at the ablation of superficial arrhythmias, it has proven more problematic when used for deep myocardial sites or for creating transmural lesions. A number of alternatives have been developed in an attempt to access these sites. 8-mm or 10-mm catheter tips are able to create larger zones of resistive heating, delivering direct RF energy to a larger area of myocardium. A larger interface between catheter tip and blood improves cooling and allows for the delivery of more power without a rise in impedence. The clinical use of these larger catheters can, however, be limited by rapid temperature rises at the catheter-tissue interface, resulting in thrombus formation, char, and steam pop rupture of the endocardial surface. The use of irrigated ablation catheters have improved upon the ability to deliver RF energy without a sustained rise in impedance. Both open irrigated- and closed-loop irrigated catheters circulate saline along the catheter tip-myocardial interface, allowing for continued delivery of RF current without thrombus formation at the endocardial surface. Intramyocardial temperature rises accordingly without a concomitant endocardial temperature surge, creating larger and deeper myocardial ablation zones. Catheters featuring a retractable needle tipped electrode with intramyocardial saline infusion have also shown promise as a means of accessing deep myocardial circuits in ventricular tachycardia ablation, but are not currently available in the US. Transcoronary ethanol ablation has also been employed with moderate success in patients with arrhythmias resistant to endocardial catheter ablation. This technology, however, grants only limited control over the size of the resulting infarct and is restricted by the need for perfusion of the scar zone by an accessible coronary artery. Nevertheless, there remain occasions in which an arrhythmia cannot be eliminated by standard unipolar ablation technique. This is seen most frequently due to deep intramural ventricular tachycardia, sometimes encountered following myocardial infarction. Both standard and alternative ablation strategies are frequently either unavailable or inadequate for termination of these arrhythmias. Recently, several centers have employed irrigated bipolar ablation (BA) to target arrhythmias not amenable to unipolar ablation. During BA, two catheters are connected to either pole of an RF generator, allowing either catheter to function as the active catheter and the other the return catheter. Rather than being dispersed between the catheter tip and a distant grounding pad, BA concentrates energy between two catheter tips positioned on opposing sides of a target scar. BA may thus improve lesion transmurality through synergistic, simultaneous heating and increased current density leading to concentrated thermal injury. Initial experience in the use of BA technology in mammalian hearts demonstrated that it could successfully be applied to create discrete areas of myocardial necrosis with minimal risk of complication. When compared to unipolar ablation, several studies suggested that BA could create larger areas of necrosis and transmural lesions with only rare episodes of perforation. Subsequent experience in human hearts was predominantly surgical: a large number of observational studies and reviews demonstrated the effectiveness and safety of BA in patients undergoing pulmonary vein isolation and Cox-Maze surgery as either isolated procedures or as adjuncts to valve replacement or coronary artery bypass surgery. Despite its broad use during surgical ablation, the application of BA during catheter-based therapies is limited. Recently, our group demonstrated the utility of BA in both an in vitro model and in a series of patients with arrhythmia resistant to unipolar ablation. When compared to unipolar RF ablation, BA was found to be more likely to achieve transmural lesions in a porcine heart model (33% vs 82%, respectively, p = 0.001) and could do so in tissue up to 25 mm thickness. Clinically, all septal atrial flutters, 5 of 6 septal VTs, and 2 of 4 free-wall VTs were successfully acutely terminated. The proposed study will further examine the role of BA in patients with ventricular tachycardia resistant to standard ablation techniques.

Interventions

DEVICEBipolar Ablation

Patients will undergo bipolar ablation if unipolar ablation unsuccessful

Sponsors

Biosense Webster, Inc.
CollaboratorINDUSTRY
Srinivas Dukkipati
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥ 18 years of age. * The study will include all forms of scar VT--both ischemic (post-myocardial infarction) and non-ischemic (eg sarcoid, amyloid, dilated)--as determined by cardiac MRI and/or voltage mapping at the time of VT ablation. * Intramural VT not terminable with unipolar ablation once enrolled in the Bipolar study or previous failed unipolar ablation within 6 months prior to enrollment. * Ability to understand the requirements of the study and sign the informed consent form. * Willingness to adhere to study restrictions and comply with all post- procedural follow-up requirements * Projected lifespan greater than 1 year.

Exclusion criteria

* Tissue Thickness less than 5 mm as assessed by electroanatomic mapping, CT, or MRI. * MI or CABG within 6 weeks. * NYHA Class IV CHF. * Women known to be pregnant or to have positive beta-HCG. * Participation in another study that would interfere with this study.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT)6 monthsFreedom from recurrent VT at 6 months, defined as sustained ventricular tachycardia lasting longer than 30 seconds and identified due to clinical symptoms or during device interrogation.

Secondary

MeasureTime frameDescription
Number of Procedural Complications6 monthsTotal number of procedural complications which includes death, stroke, MI, heart failure, conduction abnormalities, pericardial effusion requiring drainage, hematoma, pseudoaneurysm
Number of Participants With Post-ablation Inducibility of VT6 monthsNumber of participants to indicate incidence of the induction of any sustained arrhythmia post-ablation, with a duration \> 15 seconds of monomorphic VT (MMVT). Post ablation inducibility is measured via program stimulation.
Time to Arrhythmia Termination for the Bipolar Group Onlythrough termination, up to 60 secondsWhen bipolar ablation is performed during ongoing Ventricular Tachycardia (VT), the time to termination is the amount of ablation time that was necessary to cause VT to stop (terminate)
Total Duration of Bipolar Ablationaverage of 345 minutesDuration of bipolar ablation is the total procedure time
Number of of Participants With Mortality6 monthsNumber of participant from all cause mortality

Countries

United States

Participant flow

Participants by arm

ArmCount
Bipolar Ablation
Participants who underwent bipolar ablation after unipolar ablation unsuccessful
49
Patient Registry
Participants in Patient Registry after standard radiofrequency (VT) unipolar radiofrequency (RF) ablation was successful
60
Total109

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Arm AssignmentWithdrawal by Subject001
VT Induced AblationScreening Failures3600

Baseline characteristics

CharacteristicBipolar AblationPatient RegistryTotal
Age, Continuous62.88 years
STANDARD_DEVIATION 11.29
63.1 years
STANDARD_DEVIATION 11.31
63 years
STANDARD_DEVIATION 11.24
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
2 Participants6 Participants8 Participants
Sex: Female, Male
Male
47 Participants54 Participants101 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
9 / 495 / 60
other
Total, other adverse events
14 / 498 / 60
serious
Total, serious adverse events
26 / 4925 / 60

Outcome results

Primary

Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT)

Freedom from recurrent VT at 6 months, defined as sustained ventricular tachycardia lasting longer than 30 seconds and identified due to clinical symptoms or during device interrogation.

Time frame: 6 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Bipolar AblationNumber of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT)16 Participants
Patient RegistryNumber of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT)29 Participants
Secondary

Number of of Participants With Mortality

Number of participant from all cause mortality

Time frame: 6 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Bipolar AblationNumber of of Participants With Mortality9 Participants
Patient RegistryNumber of of Participants With Mortality5 Participants
Secondary

Number of Participants With Post-ablation Inducibility of VT

Number of participants to indicate incidence of the induction of any sustained arrhythmia post-ablation, with a duration \> 15 seconds of monomorphic VT (MMVT). Post ablation inducibility is measured via program stimulation.

Time frame: 6 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Bipolar AblationNumber of Participants With Post-ablation Inducibility of VT6 Participants
Patient RegistryNumber of Participants With Post-ablation Inducibility of VT5 Participants
Secondary

Number of Procedural Complications

Total number of procedural complications which includes death, stroke, MI, heart failure, conduction abnormalities, pericardial effusion requiring drainage, hematoma, pseudoaneurysm

Time frame: 6 months

ArmMeasureValue (NUMBER)
Bipolar AblationNumber of Procedural Complications31 events
Patient RegistryNumber of Procedural Complications19 events
Secondary

Time to Arrhythmia Termination for the Bipolar Group Only

When bipolar ablation is performed during ongoing Ventricular Tachycardia (VT), the time to termination is the amount of ablation time that was necessary to cause VT to stop (terminate)

Time frame: through termination, up to 60 seconds

ArmMeasureValue (MEAN)Dispersion
Bipolar AblationTime to Arrhythmia Termination for the Bipolar Group Only14.33 secondsStandard Deviation 10.29
Secondary

Total Duration of Bipolar Ablation

Duration of bipolar ablation is the total procedure time

Time frame: average of 345 minutes

ArmMeasureValue (MEAN)Dispersion
Bipolar AblationTotal Duration of Bipolar Ablation342.22 minutesStandard Deviation 133.82
Patient RegistryTotal Duration of Bipolar Ablation317.33 minutesStandard Deviation 128.98

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026